08:00 , Feb 14, 2008 |  BC Innovations  |  Targets & Mechanisms

Cancerous RAGE

Mounting evidence has linked chronic inflammation and cancer, but the sheer number of pathways and molecules that could be involved has slowed the identification of the molecular mechanisms that may lead inflamed tissue to become...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Company News

NTT, Synvista deal

Novel will develop a topical cream formulation of ALT-2074 to treat psoriasis for Synvista. Synvista plans to start an Israeli Phase II trial of the new formulation to treat plaque psoriasis in mid-2008, with data...
07:00 , Jul 30, 2007 |  BC Week In Review  |  Company News

Alteon cardiovascular, endocrine news

The company changed its name to Synvista Therapeutics Inc. and its ticker to SYI. Alteon Inc. (ALT), Montvale, N.J.   Business: Cardiovascular, Endocrine  ...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Clinical News

Organoselenium: Phase II started

ALT began a double-blind, placebo-controlled, U.S. Phase II trial (Study 201) in 60 patients with the haptoglobin 2-2 phenotype. Alteon Inc. (ALT), Parsippany, N.J.   Oxis International Inc. (OXIS; Euronext:OXIS), Foster City, Calif.   Product:...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

Alteon, BioRap Technologies Ltd., Oxis deal

ALT and BioRap expanded a 2005 deal to give ALT rights to all BioRap’s cardiovascular diagnostic technologies. BioRap will receive an upfront payment and research funding and is eligible for milestones and royalties. The original...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Clinical News

Organoselenium: Phase II start

Next quarter, ALT will start a Phase II trial in diabetic patients expressing the Haptoglobin 2-2 genotype. The company got an exclusive license to ALT-2074 from OXIS last week. Alteon Inc. (ALT), Parsippany, N.J.  ...
08:00 , Feb 26, 2007 |  BC Week In Review  |  Clinical News

Alteon preclinical data

In a rat model of peritoneal dialysis, alagebrium reversed the structural deficits of A.G.E. accumulation and improved the functional transport attributes of the peritoneal membrane. Data were presented at the Annual Dialysis meeting in Denver....
08:00 , Nov 20, 2006 |  BC Week In Review  |  Clinical News

Alteon, Oxis preclinical data

In a mouse model of diabetic heart injury, ALT-2074 reduced myocardial injury by >80% in animals with haptoglobin (Hp) genotype Hp 2-2 but not in those with Hp 1-1. ALT-2074 is a glutathione peroxidase mimetic....
08:00 , Oct 30, 2006 |  BioCentury  |  Finance

Ebb & Flow

One of the signs of a maturing sector is when the fortunes of one company don't cause either panic or euphoria in the rest of the group. Two examples in Europe last week - one...
07:00 , Oct 2, 2006 |  BC Week In Review  |  Clinical News

Alagebrium: Phase II start

Next year, ALT will begin a double-blind, placebo-controlled, U.S. Phase II trial to improve cardiac compliance and diastolic function in about 60 aged individuals. Alteon Inc. (ALT), Parsippany, N.J.   Product: Alagebrium   Business: Cardiovascular...